

Jonathan S Berek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6575046/publications.pdf>

Version: 2024-02-01

39
papers

2,520
citations

331670

21
h-index

395702

33
g-index

43
all docs

43
docs citations

43
times ranked

3390
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology and Obstetrics, 2019, 145, 129-135. | 2.3 | 612 |
| 2 | Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2018, 143, 59-78. | 2.3 | 205 |
| 3 | Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2012, 119, S118-29. | 2.3 | 194 |
| 4 | Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer. Journal of Clinical Oncology, 2009, 27, 418-425. | 1.6 | 165 |
| 5 | The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecological Surgery, 2015, 12, 165-177. | 0.9 | 158 |
| 6 | Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. International Journal of Gynecology and Obstetrics, 2021, 155, 61-85. | 2.3 | 145 |
| 7 | Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncology, The, 2018, 19, 1117-1125. | 10.7 | 95 |
| 8 | Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy. Obstetrics and Gynecology, 2010, 116, 733-743. | 2.4 | 89 |
| 9 | Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry. Cell Reports, 2018, 22, 1875-1888. | 6.4 | 83 |
| 10 | Auranofin displays anticancer activity against ovarian cancer cells through FOXO3 activation independent of p53. International Journal of Oncology, 2014, 45, 1691-1698. | 3.3 | 82 |
| 11 | Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynecology and Obstetrics, 2015, 131, S111-22. | 2.3 | 70 |
| 12 | Immunotherapeutic approaches to ovarian cancer treatment. , 2015, 3, 7. | | 63 |
| 13 | Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019. Journal of Clinical Oncology, 2021, 39, 1631-1640. | 1.6 | 62 |
| 14 | Pharmacological activation of FOXO3 suppresses triple-negative breast cancer <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 0, 7, 42110-42125. | 1.8 | 47 |
| 15 | Impact of the 2014 Food and Drug Administration Warnings Against Power Morcellation. Journal of Minimally Invasive Gynecology, 2016, 23, 548-556. | 0.6 | 46 |
| 16 | Lymph Node-Positive Stage IIIC Ovarian Cancer: A Separate Entity?. International Journal of Gynecological Cancer, 2009, 19, S18-S20. | 2.5 | 45 |
| 17 | CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer. Journal of Immunotherapy, 2008, 31, 207-214. | 2.4 | 44 |
| 18 | FIGO staging for carcinoma of the vulva: 2021 revision. International Journal of Gynecology and Obstetrics, 2021, 155, 43-47. | 2.3 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Catumaxomab for the Treatment of Malignant Ascites in Patients With Chemotherapy-Refractory Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1583-1589. | 2.5 | 41 |
| 20 | Reprogramming ovarian and breast cancer cells into non-cancerous cells by low-dose metformin or SN-38 through FOXO3 activation. <i>Scientific Reports</i> , 2015, 4, 5810. | 3.3 | 38 |
| 21 | Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e40. | 2.2 | 31 |
| 22 | Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors. <i>Psycho-Oncology</i> , 2022, 31, 9-20. | 2.3 | 29 |
| 23 | Immunotherapy in ovarian cancer. <i>Current Problems in Cancer</i> , 2017, 41, 48-63. | 2.0 | 27 |
| 24 | Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2016, 12, 693-696. | 2.5 | 19 |
| 25 | Can Arts and Communication Programs Improve Physician Wellness and Mitigate Physician Suicide?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1820-1822. | 1.6 | 17 |
| 26 | Development of Therapeutic Vaccines for Ovarian Cancer. <i>Vaccines</i> , 2020, 8, 657. | 4.4 | 15 |
| 27 | An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 303-308. | 0.6 | 13 |
| 28 | Impact of mobile technologies on cervical cancer screening practices in Lagos, Nigeria (mHealth-Cervix): Protocol for a randomised controlled trial. <i>F1000Research</i> , 2020, 9, 322. | 1.6 | 10 |
| 29 | Predictors of Survival Outcomes After Primary Treatment of Epithelial Ovarian Cancer in Lagos, Nigeria. <i>JCO Global Oncology</i> , 2021, 7, 89-98. | 1.8 | 6 |
| 30 | Impact of Mobile Technologies on Cervical Cancer Screening Practices in Lagos, Nigeria (mHealth-Cervix): A Randomized Controlled Trial. <i>JCO Global Oncology</i> , 2021, 7, 1418-1425. | 1.8 | 6 |
| 31 | Association of Genetic Testing Results With Mortality Among Women With Breast Cancer or Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 245-253. | 6.3 | 5 |
| 32 | Management and Care of Patients With Invasive Cervical Cancer: ASCO Resource-Stratified Guideline Rapid Recommendation Update. <i>JCO Global Oncology</i> , 2022, 8, e2200027. | 1.8 | 4 |
| 33 | Association of illness mindsets with health-related quality of life in cancer survivors.. <i>Health Psychology</i> , 2022, 41, 389-395. | 1.6 | 4 |
| 34 | Salpingo-Oophorectomy at the Time of Benign Hysterectomy: A Systematic Review. <i>Obstetrics and Gynecology</i> , 2017, 129, 202-202. | 2.4 | 2 |
| 35 | ASCO 2019 meeting review. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e107. | 2.2 | 2 |
| 36 | Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes. <i>JCO Precision Oncology</i> , 2021, 5, 1853-1859. | 3.0 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Strategies and Goals: The Future of the International Gynecologic Cancer Society: IGCS Presidential Address. International Journal of Gynecological Cancer, 2010, 20, 1434-1439. | 2.5 | 0 |
| 38 | Reply to B.O. Anderson et al. Journal of Global Oncology, 2017, 3, 89-92. | 0.5 | 0 |
| 39 | 30 years of Current Opinion in Obstetrics and Gynecology: looking back and looking forward. Current Opinion in Obstetrics and Gynecology, 2018, 30, 99. | 2.0 | 0 |